Potential of PET in oncology and radiotherapy

British Journal of Radiology

Volumn 78, Issue SUPPL. 28, 2005, Pages 6-16

  Saleem, A ^a  

^a CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 3' FLUOROTHYMIDINE; 5 ETHYNYLURACIL; ANTINEOPLASTIC AGENT; BROMINE; CARBON 11; CHOLINE; CLEVUDINE; COBALT; COMBRETASTATIN; CYTOSTATIC AGENT; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUORINE 18; FLUORODEOXYGLUCOSE; FLUOROURACIL; GALLIUM 68; IODINE 124; IRON 52; KI 67 ANTIGEN; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; NITROGEN 13; OXYGEN 15; RADIOISOTOPE; RADIOLIGAND; RUBIDIUM 82; TECHNETIUM; TEMOZOLOMIDE; UNINDEXED DRUG; XR 5000; YTTRIUM; ZIRCONIUM;

ARTICLE; BRAIN TUMOR; CANCER RADIOTHERAPY; CARDIOTOXICITY; DOSE RESPONSE; DRUG METABOLISM; GASTROINTESTINAL STROMAL TUMOR; HUMAN; INTERDISCIPLINARY RESEARCH; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; METHODOLOGY; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOISOTOPE DECAY; TREATMENT PLANNING;

EID: 31544459854     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/44857153     Document Type: Article

References (52)

1. Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res 1999;5:4709-14.
2. Chung JK, Lee YJ, Kim C, Choi SR, Kim M, Lee K, et al. Mechanisms related to [18F]fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice. J Nucl Med 1999;40:339-46.
3. Waki A, Kato H, Yano R, Sadato N, Yokoyama A, Ishii Y, et al. The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro. Nucl Med Biol 1998;25:593-7.
4. Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;59:7-6.
5. Hustinx R, Pourdehnad M, Kaschten B, Alavi A. PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am 2005;43:35-47.
6. 18F-FDG. J Nucl Med 2005;46:945-52.
7. Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003;64:227-37.
8. Vrieze O, Haustermans K, De Wever W, Lerut T, Van Cutsem E, Ectors N, et al. Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? Radiother Oncol 2004;73:269-75.
9. Holloway CL, Robinson D, Murray B, Amanie J, Butts C, Smylie M, et al. Results of a phase I study to dose escalate using intensity modulated radiotherapy guided by combined PET/CT imaging with induction chemotherapy for patients with non-small cell lung cancer. Radiother Oncol 2004;73:285-7.
10. Ruysscher DD, Wanders S, Minken A, Lumens A, Schiffelers J, Stultiens C, et al. Effects of radiotherapy planning with a dedicated combined PET-CT simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study. Radiother Oncol 2005 (in press).
11. 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma. Radiother Oncol 2004;73:277-83.
12. van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388-93.
13. Pollack A, Hanlon A, Horwitz EM, Feigenberg S, Uzzo RG, Price RA. Radiation therapy dose escalation for prostate cancer: a rationale for IMRT. World J Urol 2003;21:200-8.
14. Zhou SM, Wong TZ, Marks LB. Using FDG-PET activity as a surrogate for tumor cell density and its effect on equivalent uniform dose calculation. Med Phys 2004;31:2577-83.
15. 11-choline positron emission tomography. Eur Urol 2002;42:18-23.
16. 11C-choline PET. J Nucl Med 2003;44:331-5.
17. 18F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol 2005;50:2209-24.
18. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-7.
19. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996;348:1049-54.
20. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
21. Saleem. A, Yap J, Osman S, Brady F, Suttle B, Lucas SV, et al. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet 2000;355:2125-31.
22. Saleem A, Brown GD, Brady F, Aboagye EO, Osman S, Luthra SK, et al. Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 2003;63:2409-15.
23. Steel GG, McMillan TJ, Peacock JH. The 5Rs of radiobiology. Int J Radiat Biol 1989;56:1045-8.
24. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131-46.
25. Wallace WE, Gupta NC, Hubbs AF, Mazza SM, Bishop HA, Keane MJ, et al. Cis-4-[(18)Flfluoro-L-proline PET imaging of pulmonary fibrosis in a rabbit model. J Nucl Med 2002;43:413-20.
26. Saleem A, Aboagye EO, Price PM. In vivo monitoring of drugs using radiotracer techniques. Adv Drug Deliv Rev 2000;41:21-39.
27. Glaser M, Collingridge DR, Aboagye EO, Bouchier-Hayes L, Hutchinson OC, Martin SJ, et al. Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography. Appl Radiat Isot 2003;58:55-62.
28. 124I-annexin V and PET. Nucl Med Biol 2005;32:395-402.
29. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003;21:2823-30.
30. Otsuka H, Graham M, Kubo A, Nishitani H. Clinical utility of FDG PET. J Med Invest 2004;51:14-9.
31. Saleem A, Harte RJ, Matthews JC, Osman S, Brady F, Luthra SK, et al. Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine- 4-carboxamide in patients by positron emission tomography. J Clin Oncol 2001;19:1421-9.
32. Propper DJ, de Bono J, Saleem A, Ellard S, Flanagan E, Paul J, et al. Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. J Clin Oncol 2003;21:203-10.
33. Paxton JW, Young D, Evans SM, Kestell P, Robertson IG, Cornford EM. Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylaniino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse. Cancer Chemother Pharmacol 1992;29:379-84.
34. 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 1999;5:309-17.
35. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
36. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oneol 2005;16:566-78.
37. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response Using [18 F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-82.
38. Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36:1811-7.
39. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998;25:79-83.
40. Bender H, Schomburg A, Albers P, Ruhlmann J, Biersack HJ. Possible role of FDG-PET in the evaluation of urologic malignancies. Anticancer Res 1997;17:1655-60.
41. Wells P, Gunn RN, Alison M, Steel C, Golding M, Ranicar AS, et al. Assessment of proliferation in vivo using 2-[(11)C]thymidine positron emission tomography in advanced intra-abdominal malignancies. Cancer Res 2002;62:5698-702.
42. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-6.
43. 18F-FMAU and PET. J Nucl Med 2005;46:292-6.
44. 18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 2005;32:257-63.
45. 76Br-BFU as proliferation markers. J Nucl Med 2002;43:1688-98.
46. 18F-FDG. J Nucl Med 2003;44:1426-31.
47. 18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376-81.
48. Yen RF, Chen TH, Ting LL, Tzen KY, Pan MH, Hong RL. Early restaging whole-body (18)F-FDG PET during induction chemotherapy predicts clinical outcome in patients with locoregionally advanced nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging 2005 (in press).
49. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005;16:1160-8.
50. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004;101:1776-85.
51. Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004;5:531-40.
52. Bertheau P, Lerebours F, Mounier N, de Roquancourt A, Espie M, Clot P, et al. Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer. Oncol Rep 2005;14:513-20.